15 July 2021. This report describes the demographics, clinical presentation, clinical outcomes, and risk factors among people living with HIV (PLHIV) who have been hospitalized for suspected or confirmed COVID-19.
The specific objectives of the analysis were to:
describe the clinical char...acteristics and outcomes of PLHIV hospitalized for COVID-19
assess whether PLHIV hospitalized with COVID-19 were at increased risk of presenting with severe or critical illness at admission and were at increased risk of in-hospital death compared to individuals not infected with HIV
assess risk factors associated with severe or critical illness at hospital admission and of in-hospital death among PLHIV hospitalized for COVID-19.
more
If you are living with diabetes, what is the risk that COVID-19 poses to you and how can you stay safe and healthy during the pandemic?
WHO’s Dr. Gojka Roglic explains in Science in 5.
Community health workers (CHWs) play a vital role in health service delivery, especially in countries with less resilient health systems. During any outbreak CHWs are relied on to help control the spread. However, they are often the last in line to receive necessary health products and protective eq...uipment, which affects their ability to safely serve their communities.
more
If you have recovered from COVID-19 but are still experiencing certain symptoms you could have post COVID-19 condition or "long COVID". What are these symptoms? How long do they last and are there any treatment options?
Dr Janet Diaz explains in Science in 5.
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...COVERY and REMAP-CAP randomised controlled trials triggered this guideline update, resulting in a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19.
Prior recommendations: (a) A recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (b) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (c) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (d) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (e) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (f) a conditional recommendation against remdesivir in hospitalised patients with covid-19.
more
Around the world, nurses are working under enormous pressure providing care to sick and dying patients during the pandemic. Many are faced with increased stress, and other negative effects on their mental health. They are also faced with the possibility of infection and death from COVID-19. Before t...he pandemic there was a global shortage of nurses, but this is likely to be exacerbated by the increased demands of caring during COVID-19 as well as the usual care of non-COVID patients.
more
4 August 2021. Currently, Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran) is the only COVID-19 vaccine that should be stored and transported at -60ºC to -86ºC ultra-low temperature (ULT) conditions. Prior to use the vaccine can be transferred to -20ºC freezer or +2-8ºC refrigerator at... the lower store levels and immunization service points. However, vaccine shelf life is affected when vaccine is transferred to a different storage temperature. Health workers in charge of managing the storage, transport and administration of the vaccine should be well trained to maintain vaccine quality. Good cold chain planning, strong management of vaccine supply, logistics and distribution, including installation and effective monitoring and evaluation of the performance of the storage equipment and infrastructure, are also necessary.
more
Les rassemblements sont des événements caractérisés par la con-centration de personnes dans un lieu donné, dans un but précis sur une période de temps déterminée. Le but de cette note d’orientation est de présenter la position et les orientations de l’OMS concernant la tenue de rassemb...lements pendant la pandémie de COVID-19. Elle s’adresse aux respons-ables des politiques. Les informations proviennent des publications de l’OMS et d’un examen des données probantes extraites de la littérature scientifiqu
more
he Western Pacific is the world’s most disaster-prone region. When a disaster occurs, people may need to seek accommodation in a disaster evacuation shelter. However, it may be difficult for people in a disaster evacuation shelter to avoid confined and enclosed spaces with poor ventilation; crowde...d places with many people nearby; and close-contact settings, such as close-range conversations. This document outlines key considerations and strategies that should be considered for the establishment of a disaster evacuation shelter in the context of COVID-19. In particular, considerations and strategies as outlined for the preparedness, response and recovery phases of disasters.
more
These organisations have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly for low- and middle-income countries.
The aim is to vaccinate at least 40 percent of people in every country by the end... of 2021, and at least 60 percent by mid-2022. The effort will track, coordinate, and advance delivery of COVID-19 vaccines, therapeutics and diagnostics, working with governments and partners at the global and local levels to address finance and trade barriers to ensure that vulnerable populations have access to these life-saving tools. It supports the goals of the ACT-Accelerator and complementary initiatives.
more
This resource details the long term neurolgical complication seen in COVID-19 patients.
This is SCCM curated COVID-19 microlearning content.
Cet article fait partie d’une série d’explications à propos de la mise au point et de la distribution des vaccins.
Available in English, French, Spanisch, Arabic, Chinese and Russian
Cet article fait partie d’une série d’explications à propos de la mise au point et de la distribution des vaccins.
Cet article fait partie d’une série d’explications à propos de la mise au point et de la distribution des vaccins.